Inovio Pharmaceuticals (INO) Providers Clarity on INO-4800 Vaccine Path and Funding as Expected, But New Questions Emerge - RBC
Tweet Send to a Friend
RBC Capital analyst Gregory Renza reiterated a Sector Perform rating and $12.00 price target on Inovio Pharmaceuticals (NASDAQ: INO) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
